EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE
PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)

a 2020

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)

GENOVESE, M. C.; A. LERTRATANAKUL; J. ANDERSON; K. PAPP; W. TILLETT et al.

Základní údaje

Originální název

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)

Autoři

GENOVESE, M. C.; A. LERTRATANAKUL; J. ANDERSON; K. PAPP; W. TILLETT; F. VAN DEN BOSCHC; S. TSUJI; Eva DOKOUPILOVÁ; M. KEISERMAN; X. WANG; S. ZHONG; P. ZUEGER; A. PANGAN a P. J. MEASE

Vydání

2020

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14160/20:00118263

Organizační jednotka

Farmaceutická fakulta

DOI

https://doi.org/10.1136/annrheumdis-2020-eular.1229

UT WoS

000555905000222

Klíčová slova anglicky

efficacy; safety; upadacitinib; patients; active; psoriatic; arthritis; biological disease;

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 8. 2022 14:45, JUDr. Sabina Gajdzioková

Anotace

V originále

Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment of psoriatic arthritis (PsA).

Citovat

GENOVESE, M. C.; A. LERTRATANAKUL; J. ANDERSON; K. PAPP; W. TILLETT; F. VAN DEN BOSCHC; S. TSUJI; Eva DOKOUPILOVÁ; M. KEISERMAN; X. WANG; S. ZHONG; P. ZUEGER; A. PANGAN a P. J. MEASE. EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2). 2020. Dostupné z: https://doi.org/10.1136/annrheumdis-2020-eular.1229.

@proceedings{1746217,
   author = {Genovese, M. C. and Lertratanakul, A. and Anderson, J. and Papp, K. and Tillett, W. and Van den Boschc, F. and Tsuji, S. and Dokoupilová, Eva and Keiserman, M. and Wang, X. and Zhong, S. and Zueger, P. and Pangan, A. and Mease, P. J.},
   doi = {https://doi.org/10.1136/annrheumdis-2020-eular.1229},
   keywords = {efficacy; safety; upadacitinib; patients; active; psoriatic; arthritis; biological disease;},
   language = {eng},
   title = {EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)},
   url = {https://ard.bmj.com/content/79/Suppl_1/139},
   year = {2020}
}

TY  - CONF
ID  - 1746217
AU  - Genovese, M. C. - Lertratanakul, A. - Anderson, J. - Papp, K. - Tillett, W. - Van den Boschc, F. - Tsuji, S. - Dokoupilová, Eva - Keiserman, M. - Wang, X. - Zhong, S. - Zueger, P. - Pangan, A. - Mease, P. J.
PY  - 2020
TI  - EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)
KW  - efficacy
KW  - safety
KW  - upadacitinib
KW  - patients
KW  - active
KW  - psoriatic
KW  - arthritis
KW  - biological disease;
UR  - https://ard.bmj.com/content/79/Suppl_1/139
N2  - Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment of psoriatic arthritis (PsA).
ER  -

GENOVESE, M. C.; A. LERTRATANAKUL; J. ANDERSON; K. PAPP; W. TILLETT; F. VAN DEN BOSCHC; S. TSUJI; Eva DOKOUPILOVÁ; M. KEISERMAN; X. WANG; S. ZHONG; P. ZUEGER; A. PANGAN a P. J. MEASE. \textit{EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2)}. 2020. Dostupné z: https://doi.org/10.1136/annrheumdis-2020-eular.1229.

Přehled o publikaci